#USA #Los Angeles #Cancer Research #ASCO 2026 #Oncura Health

Oncura Health's Impact at ASCO 2026

Oncura Health, formerly known as Los Angeles Cancer Network, showcased its impressive contributions to cancer research during the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. As one of the foremost gatherings for oncology professionals globally, ASCO 2026 served as a platform for Oncura's dedication to improving cancer care through community-based innovations.

A Commitment to Advancing Cancer Care

During the conference, Oncura Health's physicians, led by Dr. Ronald Tang, Dr. Lasika Seneviratne, Dr. Eric Lee, Dr. Melissa Hodeib, and Dr. Sungwon Rachel Kyung, actively participated in discussions and clinical presentations. Their engagement underscored a strong commitment to advancing cancer therapies and increasing access for the diverse communities they serve. With the evolving landscape of oncology, Oncura is paving the way for innovative treatment approaches that reach patients where they need them most.

Community-Based Research Innovations

A vital element of Oncura Health's mission involves collaboration with organizations like START Los Angeles to advance clinical research. Dr. Seneviratne emphasized the importance of conducting advanced clinical trials within community settings, making groundbreaking therapies accessible beyond academic institutions. This initiative aims to bring cutting-edge cancer treatments directly to patients in their own communities and ensure that research is reflective of real-world populations.

One hallmark of this mission is the participation in first-in-human clinical studies, exploring new mechanisms in breast cancer, such as CDK degraders. Dr. Seneviratne spoke passionately about ensuring that innovative therapies are within reach for all patients, highlighting a patient-centered approach in clinical research.

Notable Research Contributions at ASCO

The engagement of Oncura Health at ASCO 2026 bore significant fruit. Dr. Tang was recognized as a principal investigator on the COPERNICUS Phase 2b study, focused on evaluating the efficacy of subcutaneous amivantamab in combination with chemotherapy for patients suffering from EGFR-mutated advanced non-small cell lung cancer. His work amplifies the importance of tailoring treatment against specific cancer mutations.

Dr. Seneviratne also contributed to a poster presentation entitled, "Achieving epidemiologically representative enrollment and social determinants of health in the Phase III EVeRA Breast Cancer Study," which highlighted the necessity of diversity in clinical trial participants to reflect the populations affected by cancer.

Breakthrough Insights Across Tumor Types

ASCO 2026 revealed critical data across various areas of oncology. Dr. Hodeib reported groundbreaking results in gynecologic oncology, indicating that nearly 54% of women with dMMR tumors experienced a cure with immunotherapy. This marks a meaningful progression in treatment outcomes for gynecologic cancers.

Additionally, Oncura Health's physicians engaged with innovative therapies anticipated to make waves in the industry, including Datopotamab Deruxtecan—a TROP2-directed antibody-drug conjugate—and Anselamimab, targeting amyloid fibrils related to rare diseases. These therapies highlight ongoing efforts to integrate precision medicine into the oncology treatment landscape.

The organization is also making strides with ongoing clinical trials, such as EMERALD-3, which pave the way for cutting-edge therapies to be introduced into community practices.

Expanding Opportunities Post-ASCO

The impact of Oncura Health's participation at ASCO 2026 did not conclude with the conference. Enhanced visibility during the event prompted numerous inquiries from research partners and sponsors aiming to collaborate on forthcoming clinical trials. Dr. Lee articulated his enthusiasm over the increased interest, stating, "This was an incredibly productive ASCO. We are witnessing a strong desire to integrate new trials into our network, reflecting the robustness of our research initiatives and the necessity of extending access within community oncology."

Leadership and Vision for the Future

Troy Simon, CEO of Oncura Health, encapsulated the event’s significance by stating, "What we are witnessing at ASCO isn’t merely incremental change; it signifies meaningful progress across a multitude of disease areas. It is paramount that these advancements reach patients swiftly and extensively, which remains the focal point of our efforts at Oncura."

Bridging Innovation with Patient Access

Ultimately, Oncura Health's presence at ASCO 2026 illustrated a broader mission: to bridge the often-challenging gap between innovation and patient access. Through an unwavering commitment to community-centered clinical research, strategic partnerships, and a dedication to enhancing patient experiences, Oncura is working tirelessly to ensure that the latest cancer treatments become available where they are most needed—within the communities that patients call home.

By embedding advanced oncology practices in local healthcare, Oncura is not only empowering patients but driving the necessary change required in cancer care today. This focus on connecting individuals to advanced therapies within their neighborhoods will foster improved health outcomes and greater accessibility for all patients battling cancer.